Hims & Hers shares plunge 28% on concerns over weight loss business

Stock of Hors & hers healt closed the 22% Tuesday, one day after the Teleelheality Company released The fourth-quarting results that disappointed on the gross margin and worries fired on the future of their weight loss activity.

Hors & heres called 481 million 481 in the quarter, up to 95% by 246.6 million during the same period last year. Net collected Yield to 26.01 10.01, or 11 cents per part, from $ 1.25 million, or 1 cent per part, a prepared year

But the gross margin, or profit for the cost of the cost of the goods sold, it was 77%, the analysts waiting 78.4%, according to the StreetAccount.

In the quarterly of the company with investors on Monday, the financial header Yemi Ostupe told the company’s scale of company options.

Hims & the cANUE of never adjusted to procrele completed semigrate, active ingredient in Nine noralymous‘S GLP-1 ozempic weight loss medications and wegovy. Compound drugs can be produced when brand treatments are in Girlsbut the food administration and drug announced Friday that lack of semaglutide injection products has been resolved.

Due to the consecedal, ere-settle on Monday that the probably stops semituietides composed in their platform after its first quarter always. GLP-1 offer has generated more than $ 225 million in the company entries in 2024.

“I’ll have to use customers in the clients that comes that they will start alternative options on the business dosing,” Hers the cake has said on the call.

Go ahead, the company said his or her primary bidding primary consist of their oral medications and injectable medications, which one is thought of their platform this year.

Morgan stanley analists said in a note tuesday that the company report has been “a lot of digesting.” They maintained their equal assessment of weight in the purse and say they were surprised by the magnitude of the 2025 of the company.

Hims & hers said waiting between $ 2,3 billion and $ 2,4 billion in revenue this year. The company has added that their weight loss offer to generate at least $ 725 million in revenue, excluding the contributions from composed semagation.

“We’re positive on the outerpiest of the long third clue and a solid clue of his company and analysis of DTC”, Morgan Stanley analysis said.

Bank analysis said that as society could have some successful patient offers as their oral medications hangs a “brand risk” as supply.

Indiage, the raises told him to the competitors to be the competitors of them save Marketing dollars in other products and hair of publicity. They are realizing their assessment in an abode.

“In general, we will not see 2025 and think the history of the batter is likely to be in terms in terms,” ​​the bank of America wrote in a note.

The duty analysis were they thought of the way to Christmas and “aspiration,” would require “significant derration” in the use of their other weight loss products. They said they are less confident of the success of these offers.

Even so, analysts increased their price target on the stock at $ 27 from $ 25.

“We know an entry point more than concellement on Ex-GLP growth – Glp – GLP – becoming more constructive”, they wrote in a Note Monday.

– Michael of CNBC Failed Contributed to this report.